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Background: Mantle cell lymphoma (MCL) is a well-defined aggressive lymphoid neoplasm characterized by
proliferation of mature B-lymphocytes that have a remarkable tendency to disseminate. This tumor is considered as
one of the most aggressive lymphoid neoplasms with poor responses to conventional chemotherapy and relatively
short survival. Since cyclin D1 and cell cycle control appears as a natural target, small-molecule inhibitors of
cyclin-dependent kinases (Cdks) and cyclins may play important role in the therapy of this disorder. We explored
P276-00, a novel selective potent Cdk4-D1, Cdk1-B and Cdk9-T1 inhibitor discovered by us against MCL and
elucidated its potential mechanism of action.
Methods: The cytotoxic effect of P276-00 in three human MCL cell lines was evaluated in vitro. The effect of
P276-00 on the regulation of cell cycle, apoptosis and transcription was assessed, which are implied in the
pathogenesis of MCL. Flow cytometry, western blot, immunoflourescence and siRNA studies were performed. The
in vivo efficacy and effect on survival of P276-00 was evaluated in a Jeko-1 xenograft model developed in SCID
mice. PK/PD analysis of tumors were performed using LC-MS and western blot analysis.
Results: P276-00 showed a potent cytotoxic effect against MCL cell lines. Mechanistic studies confirmed down
regulation of cell cycle regulatory proteins with apoptosis. P276-00 causes time and dose dependent increase in the
sub G1 population as early as from 24 h. Reverse transcription PCR studies provide evidence that P276-00 treatment
down regulated transcription of antiapoptotic protein Mcl-1 which is a potential pathogenic protein for MCL. Most
importantly, in vivo studies have revealed significant efficacy as a single agent with increased survival period
compared to vehicle treated. Further, preliminary combination studies of P276-00 with doxorubicin and bortezomib
showed in vitro synergism.
Conclusion: Our studies thus provide evidence and rational that P276-00 alone or in combination is a potential
therapeutic molecule to improve patients’ outcome in mantle cell lymphoma.
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Mantle cell lymphoma (MCL), an aggressive B-cell ma-
lignancy constitutes about 4-10% of all non-Hodgkin
lymphomas (NHLs) population [1]. It exemplifies its
clinical onset by a typical gathering of CD20+/CD5+ B
cells in lymph nodes, spleen, bone marrow, and blood
[2]. Classic (80-90% cases) and blastoid (10-20% cases)
are the two powerful variants recognized where the lat-
ter is associated with inferior clinical outcome and poor
prognosis [1,3-5]. Although treatment with combination
chemotherapeutic regimens can be effective, virtually all
patients relapse and the outcome of patients remains
poor, with a median survival of only 3-5 years [6,7]. Cur-
rently available therapies including high-dose chemo-
therapy followed by stem cell transplant, and monoclonal
antibody therapy have shown limited success [2,8]. No
therapy has been effective enough to extend the overall
survival time of patients with MCL. Thus, it remains in-
curable with current therapeutics available and awaits
more effective treatment approaches [9].
Chromosomal translocation t(11;14)(q13;32) between
the IgH and Bcl-1 genes, which results in constitutive
overexpression of cyclin D1, represents the hallmark of
MCL and seemingly one of the critical oncogenic event,
making MCL a genomically highly unstable disease
[10-13]. Cyclin D1 coupled with Cdk4 regulates the
G1-S transition of the cell cycle and hence this overex-
pression of cyclin D1 in MCL was thought to contribute
to uncontrolled growth. Cyclin D1 overexpression con-
tributes to the lymphomagenesis in MCL by overcoming
the suppressor effect that retinoblastoma protein (RB)
performs in the G1/S transition [1,14]. RB1 seems to be
normally expressed in the majority of MCL cases and
the protein appears to be hyperphosphorylated [15], par-
ticularly in highly proliferative blastic variants [16].
Enhanced proteolytic degradation of Cdk inhibitors such
as p27 and p21 is also observed in MCL [17]. The ex-
pression of antiapoptotic members of the Bcl-2 family
appears to be one important factor in the acquisition of
clinical resistance by MCL cells [18]. From a mechanistic
perspective, high levels of expression of the antiapopto-
tic protein Mcl-1 have been shown to correlate with
high-grade morphology and a high proliferative state in
MCL [17,19]. In addition, constitutively active STAT3
contributes to the malignant phenotype of MCL by pro-
moting uncontrolled cell growth and survival through
dysregulated protein expression, including that of inter-
leukins viz; IL-6 and IL-10 [7].
P276-00, a novel small molecule inhibitor of cyclin-
dependent kinases (Cdks), is currently in Phase II clin-
ical trials. It shows better selectivity towards Cdk9-T1,
Cdk4-D1 and Cdk1-B as compared with Cdk7-H and
Cdk2-E [20,21]. Recently, we showed that it inhibits
transcription in multiple myeloma cells by inhibitingCdk9-T1 which plays a positive regulatory role in tran-
scription [22]. In the present study, we have evaluated
and efficacy of P276-00 against MCL. Our hypothesis is
that P276-00 being a potent Cdk4-D1 inhibitor will in-
duce rapid cell death in MCL cells which overexpress
cyclin D1. Also, its ability to down regulate anti-apoptotic
protein Mcl-1 would contribute to its cytotoxic activity
for MCL cells. Thus, we provide in vitro and in vivo evi-
dence for use of P276-00 as a promising therapeutic
agent for the treatment of patients with MCL.
Results and discussion
Results
Cytotoxic potential of P276-00 against MCL
All the three MCL cell lines in the presence of increas-
ing concentrations of P276-00 showed significant dose-
dependent cytotoxicity as compared to vehicle treated
cells (p < 0.0001). P276-00 resulted in dose and time
dependent cytotoxicity with inhibitory concentration of
50% (IC50) ranging from 0.35 μmol/L in Jeko-1 and Mino
and 0.5 μmol/L in Rec-1 after 48 h (Figure 1A, B, C,
Table 1). Earlier, we have shown that P276-00 is less cyto-
toxic to resting hPBMCs as compared to conconavalin A
(ConA) stimulated hPBMCs [22,23]. These data indicate
that P276-00 selectively induces higher cytotoxicity in pro-
liferating cells viz. MCL cells and stimulated hPBMCs, but
lesser in quiescent (unstimulated) hPBMCs.
Jourdan and colleagues [5] reported that interleukin-6
(IL-6) and insulin-like growth factor-1 (IGF-1) aggravate
growth and prevent apoptosis in MCL cells. Treatment
of MCL cells with P276-00 overcomes this protective
effect of IL-6 and IGF-1 as observed with no change in
IC50s in presence of IL-6 and IGF-1 on MCL cell growth
(data not shown).
P276-00 inhibited the expression of positive regulators of
cell cycle and short-lived oncoproteins
Previous studies showed that transcriptional inhibition
of anti-apoptotic proteins is a key mechanism for Cdk9
inhibitor-induced cell death in indolent B-cell malignan-
cies [22]. P276-00 being a potent inhibitor of Cdk9-T1,
we studied its effect on MCL cells. It significantly
inhibited the phosphorylation of RNA Pol II CTD 6 h
onwards and continued till 18 and 24 h of treatment
(Figure 2A, B, and C). Recently, we have shown similar
results in multiple myeloma cells and results were attrib-
uted to higher selectivity of P276-00 for Cdk9 than Cdk7,
which is responsible for serine 5 phosphorylation of CTD
of RNA Pol II [20,22]. In MCL cells levels of cyclin T1
were also significantly reduced at all the three time
points. Owing to inhibition of transcription, rapid down
regulation of a short-lived protein Mcl-1 was observed
especially in Jeko-1 cells. P276-00 being a potent Cdk in-
hibitor we studied its effect on cell cycle proteins and
Jeko-1






































































Figure 1 P276-00 mediated cytotoxic effect in MCL cell lines: Dose and time dependent analysis. The effect of P276-00 on viability of
MCL cells was determined by CCK8 assay. Mantle cell lymphoma cell lines (A) Jeko-1, (B) Mino, and (C) Rec-1 were cultured in the presence of
increasing concentrations of P276-00 (0.01-3 μmol/L) for 48 and 96 h. P276-00 showed IC50 of 0.35 μmol/L at 48 hr and 0.22 μmol/L at 96 hr in
Jeko-1 cells. In Mino and Rec-1 the IC50 were 0.5 μmol/L at 48 hr and 0.21-0.33 μmol/L at 96 hr (Table 1). Data presented as the average ± SE of
three independent experiments.
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D1 protein levels and pRbSer780 which was also confirmed
by immunofluorescence in Mino after 6 h of treatment
(Figure 2D). Cdk4 levels were decreased in Jeko-1 cells
after 6 h and after 24 h in Mino and Rec-1 cells. Interest-
ingly p21 and p27 proteins were found to be increased
after P276-00 treatment in Jeko-1 and Mino cells
respectively at IC50 concentration. Mino cells whichTable 1 IC50 (μmol/L) for P276-00 and roscovitine in




48 h 96 h 48 h 96 h
Jeko-1 0.35 ± 0.047 0.21 ± 0.055 25.3 ± 1.83 18 ± 2.82
Mino 0.5 ± 0.28 0.25 ± 0.01 18.1 ± 4.38 14.56 ± 4.55
Rec-1 0.5 ± 0.24 0.33 ± 0.028 32 ± 1.0 40.1 ± 1.27harbour wild type p53 showed marked increase in p53
levels (Figure 2B). Increase in the levels of cleaved PARP,
a marker for apoptosis was observed in Jeko-1 and Rec-1
cells concomitant with apoptotic cell death. Of all the
three cell lines, Rec-1 cell line was found to be the most
sensitive. It showed significant down regulation of key
proteins such as pRbSer780, cyclin T1 and pRNA pol
IISer 2/5 after as early as 6 h of treatment.
P276-00 treatment induces apoptosis of MCL cells in a
time- and dose-dependent manner
Cell cycle analysis was performed on MCL variant cells
after P276-00 treatment. As demonstrated in Figure 3A,
B, C and D P276-00 causes induction of apoptosis in
asynchronous population of MCL cell lines when
exposed to IC50 and 3 times (3X) IC50 concentrations.




























































































































































































Figure 2 (See legend on next page.)
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Figure 2 P276-00 on positive regulators of cell cycle along and anti-apoptotic protein: Western blot analysis of cell cycle proteins at
designated time intervals after treatment of (A) Jeko-1, (B) Mino and (C) Rec-1 cells with P276-00. Jeko-1 and Mino cells (1-control, 2- IC50
treated and 3- 3X IC50) were incubated with 0.3 and 1 μmol/L P276-00 followed by protein isolation for Western blotting. Rec-1 cells (1-control
and 2- treated) were treated at 1.5 μmol/L (3X IC50) of P276-00 and it showed marked decrease in all cell cycle related protein level in time
dependent manner. Marked down regulation of anti apoptotic protein, Mcl-1, were also seen from early time point in all three cell lines.
Densitometric analysis of cyclin D1 expression was done using ImageJ software. (D) Regulation of cyclin D1 protein levels and Rb phosphorylation
by P276-00 was confirmed by immunofluorescence in Mino after 6 h of treatment. Blue: DAPI (nuclear stain); Green: cyclin D1; Red: pRbSer780.
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(70-80% sub-G1 fraction). P276-00 doesn’t allow cells to
enter G1 phase and causes significant shift of cells from
G0-G1 phase to sub-G1 phase.
P276-00 rapidly down regulates Mcl-1 transcription
To confirm that the loss of Mcl-1 protein was due to
decreased in transcription, the levels of Mcl-1 mRNA
following P276-00 treatment were measured by reverse-
transcription PCR. Tubulin was used as a control. P276-00
caused a rapid reduction of Mcl-1 mRNA in Jeko-1 cell
line from 6 h of treatment with the levels further decreas-
ing up to 24 h. It confirmed that the loss of Mcl-1 pro-
tein was due to a block in transcription (Figure 4A, B).
Effect of siRNA depletion of Mcl-1 and cyclin D1 on survival
of MCL cells
Further we proposed to validate role of cyclin D1 and
Mcl-1 in MCL survival using RNA interference (RNAi)
approach. siRNAs against Mcl-1 and cyclin D1, which
are critical proteins for MCL survival and prolifera-
tion, reduced respective protein levels by 60% in Jeko-1
(Figure 4C). There was significant reduction of cell via-
bility at 24 and 48 h with Mcl-1 siRNA and cyclin D1
siRNA at 48 h post transfection. These results highlight
the crucial role of Mcl-1 and cyclin D1 in survival of
MCL cells. When siRNA treatment was combined with
P276-00 significant decrease in percentage survival of
cells was observed compared to scrambled siRNA treat-
ment (Figure 4D). Cyclin D1 and Mcl-1 siRNA treated
cells in combination with P276-00 showed significant
growth reduction at 24 h. At later time point of 48 h,
P276-00 with Mcl-1 siRNA showed marked reduction in
survival as compared to drug alone (Figure 4D).
Anti-tumor effect of P276-00 in xenograft model of MCL
In vivo P276-00 showed significant tumor growth inhib-
ition of 91% at 50 mg/kg with stable disease throughout
the schedule (Figure 5A and B). Kaplan Meier survival
curve graph (Figure 5B) showed that mice treated with
50mg/kg P276-00 (n =10) have amedian survival of 68 days
(95% confidence interval), which is significantly longer
than the median survival of 58 days (95% confidence inter-
val) in control SCID mice. The log-rank test indicated an
overall statistically significant difference in survival ofP276-00 treated group as compared to vehicle treated
group (*p = 0.0366). In PK–PD studies, intratumoral levels
of P276-00 reached beyond its effective concentration
(Figure 5E) which correlates effectively with significant
down regulation of positive regulators of cell cycle
(Figure 5C and D).
Bortezomib and doxorubicin synergize the cytotoxic effect
of P276-00 in MCL
We next combined P276-00 with bortezomib and doxo-
rubicin at suboptimal doses. Results indicate that the
combination was synergistic as studied by Chou-Talalay
method to calculate combination index (CI) [24]. Borte-
zomib (100 nM) and doxorubicin (1000 nM) with P276-
00 showed synergism with CI values ranging from 0.56
to 0.83 (Figure 6A and 6B).
Discussion
Recent advances in the understanding of biology of
MCL cells are offering new perspectives for the design
of targeted therapeutic strategies. The t(11;14) (q13;q32)
translocation occurs in an immature B cell and results in
the ectopic and deregulated expression of cyclin D1 and
early expansion of tumor B cells in the mantle zone
areas of lymphoid follicles. This translocation is consid-
ered a primary pathogenesis event that deregulates the
cell-cycle control, probably by overcoming the suppres-
sor effect of retinoblastoma 1 (RB1) and cell-cycle in-
hibitor p27. Since defects in cell cycle regulation and
apoptosis are primary events in MCL, small-molecule
inhibitors of Cdks may play an important role in the
therapy of this disorder. Earlier data from our laboratory
has shown that P276-00, a Cdk inhibitor inhibits cyclin
D1 and down regulates Cdk4 specific phosphorylation of
RB at Ser780 (pRbSer780) along with up regulation of p27
and p21 in breast and lung cancer cell lines [20,21].
Hence, the present study was designed to evaluate the
therapeutic implication of P276-00 in MCL.
In this study, we first demonstrated that P276-00 dir-
ectly inhibited the growth of three MCL cell lines in time
and dose dependent manner. It has shown potent cyto-
toxicity against both nodal and blastic variant MCL cells
indicating potential therapeutic implication. Interestingly,
our earlier data [20,22] showed that the same treatment
did not affect the growth of normal resting hPBMNCs

































































































































Figure 3 (See legend on next page.)
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Figure 3 Effect of P276-00 treatment induces apoptosis in MCL cell lines : Cell-cycle analysis by PI staining was performed on (A)
Jeko-1, (B) Mino and (C) Rec-1, cultured with media alone or IC50 and 3X IC50 of P276-00 for the 24, 48, and 96 h time point. Cells were
processed and analyzed by flow cytometry as described in Materials and Methods. Histogram shows shift of cells from G1 phase (M1) to
apoptotic phase (M4). Results shown are representative of three independent experiments. Percent change in G1 or S-phase cells was normalized
to DMSO vehicle control (D) Compiled data shows dose and time dependant increase in apoptotic cells in all three MCL cells (*** p < 0.0001).
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Figure 4 (A) Mcl-1 mRNA measured by reverse transcription PCR in Jeko-1 cells with (1.5 μmol/L) or without (control) P276-00
treatment at indicated time points (B) Densitometric representation of RT-PCR indicating statistically significant differences compare
to control (C) Western blot analysis of protein expression at 48 h after transfection with siRNAs (D) Effect of cyclin D1 and Mcl-1 siRNA
in Jeko-1 cells. Cells were transfected with siRNAs i.e. control siRNA (control) and cyclin D1 (cyc D1) or Mcl-1 or the combination of both the
siRNAs (cyclin D1 +Mcl-1) with P276-00. Columns, mean percentage of live cells after transfection (treated) from two independent experiments;
bars, SD. **, *** significantly different from control siRNA transfected group (** p = < 0.01; *** p = < 0.001).
Shirsath et al. Molecular Cancer 2012, 11:77 Page 7 of 12
http://www.molecular-cancer.com/content/11/1/77




























P276-00  50 mpk/ip
Values are mean± SE of Ten animals per 
group (p <0.0001)
D





Figure 5 (See legend on next page.)
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Figure 5 P276-00 in vivo anti-tumor efficacy as single agent and its pharmacokinetics/pharmacodynamic relationship. (A) Treatment
with P276-00 in Jeko-1 xenograft by i.p. injection showed significant dose dependent tumor growth inhibition of 91% at 50 mpk with tumor
regression on day 8 (***p = 0.0001) and stable disease throughout the schedule (B) P276-00 prolonged survival of tumor bearing SCID mice by
two weeks compared to untreated shown using Kaplan Meier survival curve (*p = 0.0366) (C) Protein expression analysis of the tumor samples
showed target engagement with marked inhibition of cell cycle regulating and antiapoptotic proteins (D) Densitometric analysis of protein
expression in tumor samples showing decrease in levels of proliferation and survival markers (E) High intratumoral levels of P276-00-detection by
LC-MS for Jeko-1 tumor samples.
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compound was able to induce apoptosis and caused an
accumulation of cells in G1-S phase of the cell cycle in
all three MCL cell lines. This could be due to significant
reduction in cell cycle regulators viz. protein levels of
cyclin D1, pRbSer780 and Cdk4 along with down regula-
tion of antiapoptotic protein Mcl-1. Earlier studies have
also shown that Cdk inhibitors CYC202 and flavopiridol
decrease the levels of cyclin D1 in MCL [6]. Moreover
P276-00 showed down regulation of an important regu-
lator, pRbSer780 and total Cdk4 which initiates the G1-S
transition of the cell cycle. Knockdown of Mcl-1 using
siRNA in MCL cells lead to significant apoptosisFigure 6 Combination studies of standard therapies with P276-00. P2
bortezomib at 100 nM and doxorubicin at 1000 nM. Combination index (C
(100 nmol/L) and (B) Doxorubicin (1 μmol/L) are represented, with synergisindicating its importance in cell survival. Similar results
have been observed by Chen et al previously [9]. We
have shown that in addition to cell cycle protein levels,
P276-00 also inhibited transcription of key survival pro-
tein Mcl-1 which could be attributed to P276-00 effect
on Cdk9 inhibition [22]. Earlier reports indicated that
MCL cells use multiple survival pathways to evade
apoptosis, which possibly renders them resistant to a
variety of therapeutic interventions and hence targeting
cyclin D1 alone may not prove to be an effective strat-
egy, especially for MCL blastic variant in which expres-
sion of Mcl-1 has been shown to be associated with
aggressive phenotype [9,19]. Rapid apoptosis in Jeko-176-00 has synergistic anti MCL activity when combined with
I) was calculated using CompuSyn software. Data for (A) Bortezomib
m noted at given concentration of P276-00 and CI of less than 1.
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short-lived protein Mcl-1.
In addition to deregulated cell cycle control, it is clear
that aberrant apoptotic and pro inflammatory pathways
play an important role in pathogenesis of MCL [1].
Therefore, it was interesting to understand combination
effects of P276-00 with standard-of-care for MCL. Pre-
liminary combination studies of P276-00 with pro-
teasome inhibitor bortezomib and doxorubicin were
found to be synergistic. Further potential combination
approaches need to be addressed. Notably, triple com-
bination of siRNA for cyclin D1 and Mcl-1, with P276-
00 is significantly effective as compared to drug alone
suggestive of the need for inhibition of multiple path-
ways for proficient therapy for MCL. Of importance, the
in vivo efficacy in MCL xenograft in SCID mice model
demonstrates that P276-00 significantly inhibited tumor
growth and prolonged the survival of tumor bearing
mice. PK-PD studies on the tumor samples clearly dem-
onstrated down regulation of protein levels for cyclin
D1, pRbSer780 along with antiapoptotic proteins viz. Mcl-1
Bcl-2 and Bcl-XL. This indicates that the significant anti-
tumor effect is due to frank apoptosis and it was associated
with peak P276-00 plasma and tumor concentration of
5–16 μmol/L in Jeko-1 and Mino tumor samples. Im-
portantly, we observed two times higher parent com-
pound in tumors as compared to plasma indicating that
in vivo P276-00 is effective and therapeutic to MCL.
Conclusions
In summary, we investigated the action of P276-00, a Cdk
inhibitor in three MCL cell lines. Our results show that
treatment of MCL cells with P276-00 down regulated im-
portant proteins which contribute to pathogenesis of MCL
viz. cyclin D1 and Mcl-1 along with cell cycle regulators
viz. pRbSer780, Cdk4, Cdk9. These remarkable in vitro and
in vivo efficacies of P276-00, provides a framework forFigure 7 Schematic representation of effect of P276-00 on cell cycle r
Cdk9-T1 specific inhibitor showed potent antiprolifeartive effect in MCL cel
modulation of apoptosis.clinical application as a single agent or in combination
with conventional therapies in MCL (Figure 7). Thus
these data collectively suggest that by merely decreasing
the proliferative and survival signatures of the disease we
could possibly have a better overall prognosis of the dis-
ease. A phase II study is currently ongoing (http://www.
seattlecca.org/clinical-trials/lymphoma-UW09052.cfm).
Methods
Cell culture and reagents
Human MCL cell lines Jeko-1, Mino and Rec-1 were
obtained from ATCC (Rockville, MD, USA). All three
cell lines were cultured in RPMI-1640 medium contain-
ing 10% fetal bovine serum (FBS) (Hyclone, UT, USA),
2 mmol/L L-glutamine (Gibco, Grand Island, NY, USA),
100 U/mL penicillin and 100 mg/mL streptomycin
(Gibco). Cells were maintained at 37°C in a humidified
atmosphere containing 5% CO2. P276-00 was synthe-
sized at Piramal Healthcare Limited, Mumbai, India,
Roscovitine was purchased from Sigma (St Louis, MO,
USA). Both drugs were dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 10 mmol/L and stored at
-20°C until use; required dilutions were made in culture
medium RPMI-1640 immediately before use. All reagents
were purchased from Sigma (St. Louis, MO, USA) unless
stated otherwise.
In vitro cytotoxicity assay
Cytotoxicity of P276-00 on MCL cell lines was assessed
using a CCK-8 assay according to the manufacturer’s in-
structions (Dojindo), as mention earlier [22]. Each con-
centration was plated in triplicate. P276-00 was applied
at five concentrations (0.01, 0.1, 0.3, 1, and 3 μmol/L)
while roscovitine was at concentrations (1, 3, 10, 30 and
50 μmol/L). Cells were incubated for 48 and 96 h. At the
end of incubation period, CCK-8 was added (10 μL per
well) and absorbance was measured at 450 nm using aegulator and apoptosis in MCL. P276-00, a Cdk4-D1, Cdk1-B and
l lines by targeting positive and negative regulators of cell cycle with
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USA). Data was analyzed to determine the IC50 (concen-
tration of compound that inhibited cell growth by 50%).
Preparation and analysis of cell lysates by
immunoblotting
The human MCL cell lines were seeded at 1.5 × 106
cells/mL in T-25 flasks and treated with or without IC50
or 3X IC50 of P276-00 for various time points. Lysates
were prepared and western blotting was carried out as
described previously [22]. Following antibodies were
used: RNA polymerase II CTD phosphoserine 2/5 and
Mcl-1 (Cell signaling technology, USA), PARP and
Bcl-XL (BD pharmingen, USA), β-actin (Sigma, MO,
USA), Cdk4, pRbSer780, p21, p16, p27, p53, Bcl-2, cyclin
D1, cyclin T1, anti-rabbit–HRP and anti-mouse-HRP
secondary antibodies (Santa Cruz Biotechnology, CA,
USA).
Immunofluorescence and confocal laser microscopy
Mino cells were seeded at a density of 1×106 cells per
well of six well plate with treated cells exposed to
1.5 μmol/L P276-00 for 6 h. Cells were harvested and
processed for immunofluorescence as described previ-
ously [22].
Analysis of cell cycle distribution by flow cytometry
The human MCL cell lines were seeded in T-25 tissue
culture flasks at a density of 0.5 × 106/mL and treated
with or without (control) IC50 and 3X IC50 concentra-
tions of P276-00 for 24 h, 48 h and 96 h. Cells were har-
vested and processed for flow cytometry as described
previously [21].
RNA extraction and reverse transcription-PCR
Cells were treated and harvested identically to those pre-
pared for immunoblotting. Cell pellets were lysed and
RNA was extracted using RNAeasy kit (Qiagen, Valencia,
USA). Purified RNA was quantitated and assessed for
purity by UV spectrophotometry. cDNA was synthesized
from 2 μg RNA with Superscript III reverse transcriptase
(Qiagen). The amplification of each specific RNA was
performed in a 20 μL reaction mixture containing 2 μL
of cDNA template, PCR master mix and the primers.
The sequences of the primers were as follows:
Mcl-1 Forward: TAAGGACAAAACGGGACTGG; Re-
verse: ACATTCCTGATGCCACCTTC with annealing
temperature of 55°C and cycle no. 32, Tubulin Forward:
TCTGTTCGCTCAGGTCCTTTTGGCC; Reverse: CGT
ACCACATCCAGGACAGA with annealing temperature
of 55°C and cycle no. 32. The PCR products were loaded
onto 2% agarose gels and visualized with ethidium bro-
mide under UV light. As a control for cDNA synthesis,reverse transcription-PCR was also performed using pri-
mers specific for tubulin gene.
siRNA mediated RNA interference
Jeko-1 cells were plated in six-well plates with 0.2 × 106 per
well in FBS-free and antibiotic-free media. The cells were
transfected with siRNA (cyclin D1-specific siRNA or Mcl-1
siRNA or non-specific siRNA, QIAGEN, USA) using Lipo-
fectamine2000 Transfection Reagent (Invitrogen, Carlsbad,
CA) as per manufacturer’s instructions. For cyclin D1 and/
or Mcl-1 knockdown, the cells were treated with
100 nmol/L siRNA. After transfection, the next day P276-
00 was added (1 μmol/L) and the cells were incubated fur-
ther for another 24 h or 48 h.
Tumor xenograft model
Severe combined immunodeficient (SCID) mice were
injected in 0.2 mL volume (0.1 mL of the cell suspension
containing 1 × 107 cells and 0.1 mL of Matrigel) s.c. on
the right flank. When the tumors attained a diameter of
100 mm3, mice were randomized into 2 groups i.e ve-
hicle control (water) and P276-00 (50 mg/kg). Both the
groups were dosed i.p. with vehicle control and P276-00,
formulated in water, daily for 15 consecutive days. Ani-
mal survival was plotted using Kaplan Meier survival
curve and was monitored for 5 weeks post treatment
discontinuation. Tumors from animals were excised at
the end of the treatment post 15 min of dosing. Further
tumors were weighed and snap-frozen for protein ex-
pression analysis and pharmacokinetic studies. Protein
extracts were prepared and subjected to western blot
analysis as explained earlier, and probed with different
antibodies. Densitometric analysis of western blots was
carried out using Image J 1.42 q software. Animals were
maintained and experiments were carried out as per the
institutional animal ethical committee in compliance
with the guidelines of the Committee for the Purpose of
Control and Supervision on Experiments on Animals
(CPCSEA), India.
Statistical analysis
Statistical comparison was made using GraphPad
PRISMW (versions 3.0 and 5.0, GraphPad Software, Inc.,
USA) software where one-way and two way analysis of
variance (ANOVA) and Tukey’s multiple comparison
post-tests were used to determine significant differences
between several treatment groups. Student’s unpaired
t-test was employed when only two groups were com-
pared. Data are presented as mean ± S.E.M. of at least
three independent experiments with triplicates. Statis-
tical significance was evaluated by calculating p values,
where p < 0.05 was considered statistically significant.
(*p < 0.05; **p < 0.01, ***p < 0.001). Log-rank test was used
Shirsath et al. Molecular Cancer 2012, 11:77 Page 12 of 12
http://www.molecular-cancer.com/content/11/1/77for the animal survival study and Kaplan-Meier survival
curves were generated from this test.
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